

Jacqueline Stockley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/766395/publications.pdf>

Version: 2024-02-01

20
papers

887
citations

516561

16
h-index

752573

20
g-index

23
all docs

23
docs citations

23
times ranked

1603
citing authors

#	ARTICLE	IF	CITATIONS
1	The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. <i>Nucleic Acids Research</i> , 2013, 41, 4433-4446.	6.5	109
2	Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. <i>Blood</i> , 2013, 122, 4090-4093.	0.6	108
3	Regulation of the androgen receptor by SET9-mediated methylation. <i>Nucleic Acids Research</i> , 2011, 39, 1266-1279.	6.5	105
4	The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. <i>Nucleic Acids Research</i> , 2015, 43, 196-207.	6.5	86
5	KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade. <i>Nucleic Acids Research</i> , 2013, 41, 6892-6904.	6.5	66
6	The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. <i>Scientific Reports</i> , 2015, 5, 13426.	1.6	55
7	Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. <i>BMC Cancer</i> , 2014, 14, 977.	1.1	49
8	The RNA-binding protein hnRNPA2 regulates β -catenin protein expression and is overexpressed in prostate cancer. <i>RNA Biology</i> , 2014, 11, 755-765.	1.5	42
9	A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor-1 in a patient with chronic bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 716-725.	1.9	40
10	Identification of Novel Androgen-Regulated Pathways and mRNA Isoforms through Genome-Wide Exon-Specific Profiling of the LNCaP Transcriptome. <i>PLoS ONE</i> , 2011, 6, e29088.	1.1	39
11	A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria—A Prospective Multicentre Performance Evaluation of ADXBLADDER. <i>European Urology Oncology</i> , 2020, 3, 42-46.	2.6	33
12	Does androgen-ablation therapy (castration) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?. <i>BJU International</i> , 2013, 111, 672-682.	1.3	32
13	Docetaxel-Resistant Prostate Cancer Cells Remain Sensitive to S-Trityl-L-Cysteine-Mediated Eg5 Inhibition. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1730-1739.	1.9	30
14	Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. <i>Journal of Urology</i> , 2020, 204, 685-690.	0.2	28
15	Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. <i>BJU International</i> , 2021, 127, 198-204.	1.3	21
16	Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. <i>Endocrine-Related Cancer</i> , 2007, 14, 613-624.	1.6	18
17	Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. <i>European Urology Focus</i> , 2022, 8, 1643-1649.	1.6	9
18	Molecular Dynamics Analysis of a Novel Pro189Ser Mutation in a Patient with Glanzmann Thrombasthenia Differentially Affecting β 3 and α 3 Expression. <i>PLoS ONE</i> , 2013, 8, e78683.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. PLoS ONE, 2015, 10, e0143913.	1.1	6
20	Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced nonâ€castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 337.e1-337.e6.	0.8	4